AKI furosemide
Reading File
Finding Sources
Searching PubMed
furosemide "acute kidney injury" loop diuretics
Reading File
Finding Sources
Reading Article
PMID: 39878152
Reading File
Reading File
Excellent - I now have rich, comprehensive content. Let me compile the full answer.
Furosemide in AKI
Role and Key Principle
Furosemide (and loop diuretics generally) does not improve renal recovery or hasten resolution of AKI. Its role is purely supportive - managing fluid overload and oliguria to simplify overall care. Response to diuretic therapy is a favorable prognostic sign, but the response itself does not change outcomes.
"Diuretic therapy used appropriately neither hinders nor hastens recovery from AKI. Response to diuretic therapy is a favorable prognostic sign in AKI."
- Campbell-Walsh Wein Urology, p. Management of AKI
Indications for Furosemide in AKI
- Volume overload with oliguria - to prevent worsening fluid accumulation that may precipitate need for renal replacement therapy (RRT)
- Furosemide Stress Test (FST) - to predict AKI severity and progression
- Bridge to recovery - simplify management while awaiting spontaneous renal recovery
Furosemide is NOT indicated to:
- Convert oliguric to non-oliguric AKI as a treatment strategy
- Prevent AKI in high-risk patients (e.g., contrast nephropathy prevention - saline remains first-line)
- Accelerate tubular recovery
Dosing Strategy
| Approach | Protocol |
|---|---|
| IV bolus | Assess response within 60 minutes. If inadequate urine output, escalate dose to find threshold. Dose every 6-8 hours once threshold established. |
| Continuous infusion | If patient responds to, e.g., 60 mg IV bolus → convert to 10 mg/h infusion. Provides more consistent drug levels and may reduce complication rate. |
| Combination therapy | Add metolazone 2.5-5 mg/day (thiazide) if refractory to high-dose loop diuretic. Blocks distal Na+ reabsorption synergistically. Monitor K+ closely - hypokalemia is common. |
- Campbell-Walsh Wein Urology, p. Management of AKI
Alternative loop diuretics:
- Bumetanide and torsemide have better oral bioavailability and increased potency vs furosemide
- Torsemide has longer duration of action; may reduce hospitalizations in heart failure patients
- Ethacrynic acid - reserved for sulfonamide allergy; more ototoxic, harder to give IV
The Furosemide Stress Test (FST)
Used in patients with oliguria + volume overload (euvolemic or hypervolemic, NOT on pressors) to predict AKI severity and progression to Stage 3 / need for RRT.
Protocol:
- Give a single IV dose of furosemide:
- 1.0 mg/kg if furosemide-naive
- 1.5 mg/kg if prior furosemide exposure
- Measure urine output over the first 2 hours
- Cutoff: Urine output < 200 mL in 2 hours = high likelihood of progression to advanced AKI
The FST has good sensitivity and specificity for identifying patients who will progress, and a 2025 meta-analysis (Zhao et al., Sci Rep 2026, PMID 41813944) confirmed its predictive value for RRT requirement.
- Washington Manual of Medical Therapeutics, p. Tubular (ATN section)
- Comprehensive Clinical Nephrology 7th ed., Therapeutic Goals
Cochrane Evidence (2025)
The most current Cochrane systematic review - Hashimoto et al., Cochrane Database Syst Rev 2025, PMID 39878152 - included 64 RCTs (9,871 participants) and found:
For AKI Prevention:
- Diuretics may reduce risk of AKI (RR 0.75, 95% CI 0.61-0.92; low-certainty evidence)
- Diuretics probably reduce KRT use (RR 0.63, 95% CI 0.43-0.91; moderate-certainty evidence)
- Diuretics probably reduce mortality (RR 0.73, 95% CI 0.59-0.92; moderate-certainty evidence)
For AKI Treatment:
- Evidence base is weaker; diuretics do not clearly reduce KRT need or change prognosis once AKI is established
Key caveat: High heterogeneity (I² = 77% for AKI prevention) and mostly low-to-moderate certainty evidence across these outcomes.
Monitoring and Precautions
- Electrolytes: Hypokalemia and metabolic alkalosis are common, especially with combo loop + thiazide therapy
- Ototoxicity: High-dose furosemide (especially rapid IV infusion) - risk increases with aminoglycoside co-administration
- Volume status: Furosemide in a volume-depleted patient will worsen prerenal AKI - confirm euvolemia/hypervolemia before use
- Avoid in: Prerenal AKI without volume overload; postrenal AKI (treat obstruction first)
Summary
| Question | Answer |
|---|---|
| Does furosemide treat AKI? | No - it treats fluid overload associated with AKI |
| Does it speed up recovery? | No - but it simplifies management |
| Is diuretic response a good sign? | Yes - favorable prognostic indicator |
| FST dose (naive)? | 1.0 mg/kg IV single dose |
| FST dose (prior exposure)? | 1.5 mg/kg IV single dose |
| FST cutoff for poor prognosis? | <200 mL urine in 2 hours |
| Combo if refractory? | Add metolazone 2.5-5 mg/day |
This is a shared conversation. Sign in to Orris to start your own chat.